Corticobasal degeneration and corticobasal syndrome: A review

Clinical Parkinsonism & Related Disorders

卷:1

George P. Paraskevas¹  Vasilios C. Constantinides²  Elisabeth Kapaki²  Panagiotis G. Paraskevas²  Leonidas Stefanis³ 

[1] Corresponding author at: 1st Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, Eginition Hospital, 72 Vas. Sofias Ave., 11528 Athens, Greece.;

[2] 1st Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, Eginition Hospital, Greece;

[3] Department of Nursing, Technological Educational Institute of Crete, School of Health and Welfare Services, Greece;

关键词: Corticobasal syndrome;    Corticobasal degeneration;    Biomarkers;    MRI;    PET;    Spect;   

DOI  :  

来源: DOAJ

【 摘 要 】

Corticobasal degeneration (CBD) is a rare neurodegenerative disorder. The most common presentation of CBD is the corticobasal syndrome (CBS), which is a constellation of cortical and extrapyramidal symptoms and signs. Clinical-pathological studies have illustrated that CBD can present with diverse clinical phenotypes, including a non-fluent, agrammatic primary progressive aphasia syndrome, a behavioral, dysexecutive and visuospatial syndrome, as well as a progressive supranuclear palsy-like syndrome. Conversely, multiple pathologies, such as CBD, Alzheimer's disease and progressive supranuclear palsy may underlie a patient with CBS. This clinical-pathological overlap emphasizes the need for biomarkers that will assist in the accurate diagnosis of patients with CBS. This review presents an overview of the pathological, genetic, clinical and therapeutic characteristics of CBD, with an emphasis on the imaging (structural and functional) and biochemical (cerebrospinal fluid) biomarkers of CBD.

【 授权许可】

Unknown